Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services
Deal Size : Inapplicable
Deal Type : Inapplicable
Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)
Details : Midodrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vasoplegia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection
Details : Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2020
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Alberta Health services | Institute of Health Economics, Canada
Deal Size : Inapplicable
Deal Type : Inapplicable
Midodrine for the Early Liberation of Vasopressor Support in the ICU
Details : Midodrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Critical Illness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : Midodrine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Alberta Health services | Institute of Health Economics, Canada
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Sponsor : New Jeddah Clinic Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Midodrine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Acute Kidney Injury.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2018
Lead Product(s) : Midodrine
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Sponsor : New Jeddah Clinic Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Minimization of Intradialytic Hypotension Using Cardiography-Guided Intervention
Details : Midodrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypotension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2017
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Midodrine During Recovery From Septic Shock
Details : Midodrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypotension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2016
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Details : Midodrine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypotension, Orthostatic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2012
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Details : Midodrine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypotension, Orthostatic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2012
Lead Product(s) : Midodrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable